急性脑卒中合并重症肺炎的临床研究

Clinical study on acute stroke plus severe pneumonia

目的:探讨血必净注射液对急性脑卒中合并重症肺炎的临床疗效。方法:将急性脑卒中合并重症肺炎患者32例随机分为试验组和对照组,对照组给予常规治疗,试验组在对照组常规治疗的基础上加用血必净静脉滴注,分析比较两组的症状消失时间、降钙素原(Procalcitonin,PCT)、白细胞计数(White Blood Cell,WBC)、超敏C反应蛋白(high sensitivity C-reactive Protein,hs-CRP)、血清淀粉酶(Serum Amyloid A,SAA)水平。结果:试验组咳嗽、发热、湿啰音等症状缓解时间低于对照组(P<0.05),两组的治疗后PCT、WBC、hs-CRP、SAA水平均低于治疗前(P<0.05),但试验组改善程度优于对照组(P<0.05)。结论:血必净治疗急性脑卒中合并重症肺炎可以改善症状、降低炎症因子水平。

Objective:To investigate the clinical efficacy of the Xuebijing injection(血必净注射液)on patients with acute stroke plus severe pneumonia.Methods:Thirty-two patients with acute stroke plus severe pneumonia were randomly divided into the experimental group and the control group.The patients of the control group were given regular treatment.The patients of the experimental group were treated with the Xuebijing injection more.The symptom disappearance time,PCT,WBC,hs-CRP,SAA were compared.Results:The remission time of cough,fever and moist rale in the experimental group was shorter than that in the control group(P<0.05).After treatment,the levels of PCT,WBC,hs-CRP and SAA were lower than those before treatment(P<0.05),and the improvement of the experimental group was better than that in the control group(P<0.05).Conclusion:The Xuebijing injection treating acute stroke plus severe pneumonia could improve symptoms and reduce the level of inflammatory factors cytokines.